George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Inan,
I’m afraid there’s a big difference between gauging opinion, making an estimate and mind reading.
I said “I THINK” as opposed to your “I can easily make a case”.
probably .,.. but it really does clear out and identify idiots ...
Ray,
“ But why discuss the lack of RNS-Rs with the BB and not with the company?”
Why not? What do you think a BB is for if it’s not for sharing information and expressing opinions?
If you want to form a Scancell fan club please do so, I might even join. Presumably the membership fee will be modest compared to the £Ks I put in here.
oh ......... Ruck sorry ..
did you post this earlier ......... ???
""""""""""""""" I think 99% of us here are unhappy about the lack of communication on Covid impact.""""""""""
fantastic Mind Read that was Ruck ...... efficacy 99% How
sound case for investing ...
read Michaels post ............."""" ludicrously cheap """"
I really do hope you can think a little bit before you post ..
I agree at times we could be better informed.
But why discuss the lack of RNS-Rs with the BB and not with the company?
Inan,
No you can’t argue the case for “people”, you can only argue the case for yourself unless you are a mind reader who can read minds of people you can’t see.
The only reason you ever present for buying is the fact that you have and continue to do so.
I’m afraid that doesn’t make a sound case for investing.
I could argue the case very easily that those who really feel comfortable with the science would prefer scancell to only RNS on actual price sensitive data. Indeed the fact that some feel that more should be provided are dragging the SP back allowing those who keep building a stake to do so at a lower SP ... since April i have bought £13700 in nibbles ...
thanks ..
Yes Ivy, I think 67% of shares in PI hands (from memory)
And whilst a lot of bought in the 20s-40s and are in for the long haul, there are a lot of investors who have bought in at a wide range of prices between 3.6p and 60p and for a wide variety of reasons. So someone who managed to buy in at under 4p, see it rise to 9p and then drop back to 5.5p May well get fed up and move on. Some may have bought in purely on the Covidity news and move on with a lack of any follow up.
So whilst we as LTH may not share these views, their actions have an impact on the SP.
Just a modest level of communication could have resulted in a higher SP than it is now.
The excuse about not providing updates on progress of projects or other aspects of the business has become a very general cliche among the companies that are making insufficient progress with their projects or not much to update investors on (e.g. what happened with SCIB when SCLP went into silent mode). NDAs may address detailed terms of agreements with partners, IP information that has to remain confidential, information about a trial as it carries on (even though an interim statement may be issued. Sensitive details about discussions with the regulator may not be appropriate to reveal to the general public. However, it is misleading to say that a company can't give selectively generic project updates (e.g. when SCIB 1 is to go ahead) or information on how partherships with third parties are going. The recent example is Modi-1.
Possibly Ray.
My point is if Sally was quite happy at an AGM to answer the question with July why did the Company wait until 24th October to inform us when I recall daily BB speculation about the situation and what was issue.
No one expects SCLP to release any material news except in an RNS and that includes specific questions on funding however imo that does not preclude them from giving general updates say with RNS R or presentations or indeed answering general questions about how they make seek to finance the science moving forward.
On most other AIM Company I am in the BoD recognise their duty to regularly communicate to their SH.In fact I can think of one who is doing 3 separate presentations the next 2 days and before anyone says they have done a recent capital raise and the CEO is happy to talk about how they intend to monetise the assets.
I am in other AIM outfits which take a similar approach to here which is being circumspect in communicating with SH and not surprisingly a lot of PIs just move on.
Again would not be an issue if we had huge institutional support but that is not the case here
But didn't Sally say that the issue was between the FDA and Ichor, with Scancell just not knowing what sticking point was?
but you did make an informed judgement Ivy .. you sold. and you explained why which was fair enough ..
But can you understand why Investors get frustrated when it states a short delay and 12 months later we still don’t know what exact issue is.
This is the kind of communication which is required rather than just left in the air for us all to come to our own conclusions.
Very few PIs have an enduring confidence in any share particularly when things are nit updated so we can’t make informed judgements
Yes, I agree but the monetisation progress is something we will only know about when it happens. This includes funding for Covidity.
With the current situation, it maybe looks likely that monetisation will take place before trial data is published.
On research and development, IMO we get well informed.
Ray,
I think 99% of us here are unhappy about the lack of communication on Covid impact.
I think 100% of us know that Scancell cannot disclose anything they are not allowed to under NDA.
We are probably more split on the subject of research papers. We already have 4/5 platforms at various stages of development. I’d rather see some real progress on the ones we have already.
SCIB1 is the most clinically advanced but I get the feeling it isn’t going to be the first to produce some monetisation. So management focus has to be on selling/licensing something and getting the SCIB1 combo trial moving. A combination of products in the clinic and enough cash in the bank to see them through will work wonders for the SP.
1 run to the total
Time for Cricket ............
Bye
i presume 2918 .. ivy should be 2018
RNS ... IVY 2017
The Company has been making good progress in compiling the Investigational New Drug (IND) application to the FDA for the SCIB1 checkpoint inhibitor combination study in the US. The request by the FDA for Ichor to provide data on its second generation TriGrid electroporation device has resulted in a short delay to our IND submission. However, we expect that this will be submitted in early 2018.
so Investors knew that issues had been identified
I'm with Bermuda about the lack of a "how the business has been effected by Covid19" RNS including the SCIB1 trial.
I'm with Inan about the BOD not disclosing anything that is under an NDA. They simply cannot do that.
I'm also happy that we get good updates on how the research and development is progressing; 2 papers recently and modi1 3rd conjugate problems solved.
But anyone is free to email the BOD at any time. You may get a non-committal answer depending on the question.
Hi RR,
One and only question I asked at last AGM I attended was When did SCLP become aware of the delays in SCIB 1/Combo which was RNSd on 24th Oct,2918.
I was told by Sally Adams it was July.
Will leave it up to others to decide whether SCLP could have told us earlier or did they RNS it on 24th before the AGM.
Done ... £1000 at 5.63p ........... No fuel used ... a Green Deal
Just the weigh in Bunsie, just the weigh in!
Inan, I’ve never believed or suggested you were poor. My reference to putting “ diesel” in your car was bought about by your nit-picking when someone said “petrol” yesterday. I withdraw the suggestion.
you keep telling folks i am poor ..
what does that make you ..... oh yes a complete plank
mr last buy at 10p ... 3 years ago ... £10 a share man
It's not Friday already, surely!